Appl. No. 10/712,122 Arndt. & Resp. to Restriction Req. Restriction Requirement dated Oct 12, 2005

## **Election of Claims**

In the Office Action dated October 12, 2005, the seven pending claims in the above-referenced case were restricted into three groups. The three groups named are: Group I, claims 1-2, drawn to a method for reducing tumor burden; Group II, claims 3-4, drawn to a method for inhibiting recurrence of gross cystic disease of the breast; and Group III, claims 5-7, drawn to a method for preventing or reducing the frequency or severity of transient Ischemic attacks or strokes.

Applicants hereby elect Group I, with traverse. All of the pending claims are directed to methods for using EGFR inhibitors and, thus, are related. Applicants believe that a serious burden would not be imposed on the Examiner if all claims were included in a single application. Therefore, Applicants do not believe that it is proper to restrict the pending claims. MPEP § 803.

An amended set of claims is attached. Please enter these amended claims. New claims 8-17 have been added, all of which depend ultimately on claim 1. These claims are supported most particularly at lines 20-24 of page 2 and line 3 of page 35 through line 21 of page 38 of the specification.

## **Conculsion**

Since November 12, 2005 fell on a Saturday, Applicants believe that this response is timely filed and that no fees are now due. However, if the Examiner finds that fees are due at this, or any other time during the pendency of this application, please charge such fees to Deposit Account No. 09-0089. If the Examiner believes that any matter connected to this case can be most easily handled via teleconference, she is invited to telephone the undersigned at the direct dial number listed below.

Amgen Inc. 1201 Amgen Court West M/S AW2-D/4262 Seattle, WA 98119-3105 Respectfully submitted,

Rosemary Sweeney Reg. No. 52,264

Phone: 206-265-7817